The destination of most of the glucose taken up by tissues in response to insulin is skeletal muscle [l-41, which stores it as glycogen [5, 6] . Thus glycogen synthesis is one of the most important processes in the regulation of blood glucose by insulin. The pathway leading to glycogen begins with glucose transport into the muscle fibre, a step that is markedly increased by insulin [7, 8] . In the next three steps glucose is phosphorylated by hexokinase to glucose 6-phosphate (G6P), which is then sequentially converted into glucose 1-phosphate and UDPglucose in reactions catalysed by phosphoglucomutase and UDP-glucose pyrophosphorylase respectively. In the final step, glycogen synthase catalyses the transefer of the glucosyl moiety from UDP-glucose to pre-existing glycogen. It has been known for over 35 years that insulin activates glycogen synthase [9] . However, major questions still remain about the mechanisms involved in both the activation of glycogen synthase and the role of glycogen synthase activation in the stimulation of glycogen synthesis by insulin.
Mechanism of insulin action on glycogen synthase
Glycogen synthase is controlled by multisite phosphorylation and by several allosteric effectors, of which the activator G6P is most important [ 10,111. Two phosphorylation sites (2 and 2a) are present in the first ten amino acids in the N2-terminus of skeletal-muscle glycogen synthase, while at least seven (3a, 3b, 3c, 4, 5, la and lb) are found in a stretch of 100 amino acids at the C-terminus [ 10,111. In general, phosphorylation decreases synthase activity, but the extent of inactivation depends on the sites phosphorylated Abbreviations used: PPIG, glycogen-bound form type-1 protein phosphatase; MAP kinase, mitogen-activated protein kinase; ISPK, insulin-stimulated protein kinase; EGF, epidermal growth factor; MEK, MAP kinase kinase; GSK-3, glycogen synthase kinase 3; G6P, glu$ose-6-phosphate.
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and on the effector concentrations. G6P is able to activate fully even highly phosphorylated forms of the enzyme. Insulin activates glycogen synthase by promoting dephosphorylation of the enzyme, resulting in an increase in the -/+ G6P activity ratio and in a decrease in the concentration of G6P required to activate the enzyme [12] . In rat skeletal muscle, the phosphorylation states of sites 3(a+b+c) and site 2 (and/or 2a) are decreased in response to insulin (Table 1) [13-151. The conclusion that dephosphorylation of sites in both the N-and C-terminal domains is important in the activation of glycogen synthase is strongly supported by recent studies in COS cells where the influence of different phosphorylation sites was investigated by expressing glycogen synthases with phosphorylation sites mutated to alanine . When wild-type synthase is expressed in these cells, it becomes highly phosphorylated and has a very low -/+ G6P activity ratio. Preventing phosphorylation of the appropriate sites by mutation leads to expression of an enzyme with an increased activity ratio. Single mutations of all the known sites or collective mutations of all three site-3 serine residues (3a, 3b and 3c) had little effect on the activity ratio. Mutations of site 2 together with either site 3a or 3b were required to significantly increase the -/+ G6P activity ratio [16, 17] and to increase the accumulation of glycogen [ 17,181. T o be complete, any hypothesis for the mechanism of action of insulin on glycogen synthase must account for the multisite dephosphorylation of the enzyme that occurs in response to the hormone. The enzymes of glycogen metabolism are believed to be dephosphorylated by PPIG, the glycogen-bound form of type-1 protein phosphatase [19] . PPIG is capable of dephosphorylating all of the sites in glycogen synthase, and activation of this phosphatase would be consistent with the observed insulinstimulated dephosphorylation of sites in both the N-and C-terminal regions of the synthase. In an elegant series of studies, Cohen and co-workers Volume 25 [19] or hL [20] , and a type-I protein phosphatase catalytic subunit. &;L contains several sites for phosphorylation by different protein kinases. In vitro the glycogen synthase phosphatase activity of the enzyme was found to be increased when kL was phosphorylated in site 1 [19] . Insulin was reported to increase specifically the phosphate content of site 1 in vivo [21] and an insulin-stimulated protein kinase, designated ISPK, that selectively phosphorylated site 1 in v i m was partially purified from rabbit skeletal muscle [21] . With the subsequent discovery that ISPK was ~9 0 "~ [22] , the activation of glycogen synthase could be linked to the well-characterized MAP kinase signalling pathway, as MAP kinase was known to phosphorylate and activate p90rAk [23] . A widely accepted model emerged in which the activation of glycogen synthase could be traced via the MAP kinase signalling pathway all the way from insulin binding to synthase dephosphorylation ( Figure 1 ). Recent findings provide strong evidence that this model is incorrect. Results obtained with epidermal growth factor (EGF) in adipocytes provided the first evidence that the MAP kinase pathway was not involved in the activation of glycogen synthase by insulin [24, 25] . EGF was found to be more effective than insulin in increasing MAP kinase and ~9 0 "~ [25] . If these kinases were in the 
The two major prevailing hypotheses for the activation of glycogen synthase by insulin
The MAP kinase pathway begins with the insulin receptor which phosphorylates intracellular docking proteins, such as insulin receptor substrate-I (IRS-I). As a result, the mammalian son of sevenless (mSOS) complex is recruited via growth-factor-receptor-binding protein 2 (Grb-2) subunit, resulting in the activation of
Ras. This triggers a cascade involving the sequential activation of the protein kinases, Raf, MAP kinase kinase (MEK), MAP kinase and p90"'. PPIG may be phosphorylated and activated by p90"' in vitro, but evidence discussed in the text indicates that the MAP kinase pathway does not mediate the activation of glycogen synthase in response to insulin in skeletal muscle. Another hypothesis is that insulin activates synthase by inhibiting glycogen synthase kinase-3 (GSK-3). This pathway is thought to involve phosphoryation of IRS-I , which recruits phosphatidyl inositol 3'-OH kinase (PIK). Activation of PIK may lead to activation of the protein kinase RAC/Akt, also known as protein kinase B (PKB). RAC/Akt has been shown to phosphorylate and inactivate GSK-3. Additional work is needed to determine whether inhibition of GSK-3 mediates the activation of glycogen synthase by insulin. 
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transduction pathway leading to glycogen synthase activation, then EGF would be expected to activate the enzyme. However, unlike insulin, EGF did not activate glycogen synthase [24, 25] . Similar results were obtained with insulin and EGF in rat diaphragm muscles incubated in vitro, indicating that MAP kinase and p90nk activation are not sufficient for synthase activation in skeletal muscle [26] . Another approach to the investigation of the role of MAP kinase in cells became possible with the development of the plasma-membrane-permeable inhibitor of MEK activation, PD 098059 [27] . Incubating rat diaphragms with PD 098059 blocked the activation of MAP kinase and p90nk by insulin [26] ; however, the inhibitor did not significantly decrease the activation of glycogen synthase by insulin [26] . Taken together, the results with EGF and PD 098059 indicate that activation of MAP kinase and p90"' is neither necessary nor sufficient for the activation of glycogen synthase in skeletal muscle.
It should be stressed that results obtained thus far do not exclude the possibility that insulin activates PPIG via phosphorylation of site 1, and additional research is needed to investigate the role of the phosphatase in the activation of glycagen synthase by insulin. However, in principle, the effect of insulin on synthase need not involve direct activation of a phosphatase. 32P-Labelling studies have demonstrated that phosphate is turning over relatively rapidly in glycogen synthase [ 141. Thus net dephosphorylation could be achieved by inhibiting the activity of the appropriate protein kinase. There is evidence to support the hypothesis that the activation of glycogen synthase in response to insulin involves inhibition of GSK-3, a kinase that phosphorylates sites 3a, 3b and 3c in glycogen synthase [10, 11] . Insulin has been shown to decrease GSK-3 activity in several cell types [28, 29] . Recent findings indicate that the inhibitory effect of insulin on GSK-3 may be mediated by the kinase, RAC/Akt [30] . This kinase has been shown to phosphorylate and inactivate GSK-3 a' n vitro [30] . The sites in GSK-3 phosphorylated by RAC/Akt in vitm are the same as those phosphorylated in response to insulin. Although the available evidence is consistent with a role of RAC/Akt in the activation of glycogen synthase, it is important to keep in mind that inhibitian of GSK-3 alone cannot account for the action of insulin on glycogen synthase, since GSK-3 does not phosphorylate glycogen synthase in site 2, which is dephosphorylated in response to insulin (Table 1) . In evaluating the role of the RAC/Akt pathway in the activation of glycogen synthase by insulin, it will be important to apply the same criteria used to test the role of the MAP kinase signalling pathway. Thus experiments are needed to investigate the actions of agonists other than insulin that activate RAC/Akt in skeletal muscle. Another key experiment will be to determine whether inhibiting the effects of insulin on RAC/Akt and GSK-3 blocks the activation of glycogen synthase in skeletal muscle.
Glucose transport versus glycogen synthase
The finding by Villar-Palasi and Larner [9] that insulin activated glycogen synthase renewed a debate that has continued for over three decades. The simple central issue is whether the stimulation of glycogen synthesis by insulin is caused by a push or a pull. Briefly stated, the 'push hypothesis' is that insulin acts by activating glucose transport, thereby pushing glucose into glycogen. The 'pull hypothesis' is that by activating glycogen synthase, insulin causes intermediates in the pathway to be pulled into glycogen. Recent experiments in transgenic animals overexpressing either glucose transporters or glycogen synthase have provided new insights into the mechanisms involved in insulin-stimulated glycogen synthesis.
Glucose transport in skeletal muscle occurs by facilitative diffusion mediated by the transport protein, GLUT4 [7, 8] . At low insulin concentrations, very little GLUT4 is found at the cell surface. An increase in insulin results in translocation of GLUT4 from intracellular compartments to the plasma membrane. Glucose entry into the fibre increases as a result of the increased numbers of glucose transporters at the cell surface. Another member of the glucose transporter family [31], GLUT1, is also expressed in skeletal muscle, but at levels much lower than those of GLUT4 [7, 8] . Thus GLUTl is not thought to contribute significantly to the insulin-stimulated component of glucose transport [7, 8] . However, GLUTl may contribute to basal glucose uptake, as a large fraction of GLUTl is found at the cell surface, even in the absence of insulin [31] . Overexpressing GLUTl in muscle cells markedly increased glucose transport even in the absence of insulin [32, 33] . Skeletal muscles from transgenic mice over- Volume 
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N e w Insights into the Molecular and Cellular Regulation of Glycogen Storage and Degradation expressing GLUT1 exhibited severalfold increases in glucose uptake and in the levels of glycogen, but the transgenic muscles had glycogen synthase activities that were not significantly different from those in muscles from non-transgenic litter mates [32] . On the basis of these results it was concluded that glucose transport is the rate-limiting step for both glucose uptake and the synthesis of glycogen in skeletal muscle [32, 34] . However, it is clear from more recent findings that this conclusion is not valid under all conditions in vivo. For example, the demonstration that overexpression of hexokinase I1 in skeletal muscle increased both basal and insulin-stimulated glucose uptake by as much as 90% indicates that the rate of glucose phosphorylation may be a limiting factor for glucose uptake [35] .
Experiments in transgenic mice overexpressing glycogen synthase in skeletal muscle demonstrate that glucose transport is not strictly rate-limiting for glycogen synthesis [36] . Transgenic animals were generated that expressed a mutant form of glycogen synthase having Ser to Ala substitutions in sites 2 and 3a to increase the amount of active enzyme. Glycogen synthase activity was up to tenfold higher in the transgenic muscles ( Figure 2 ) [36] . Associated with the elevated levels of synthase were glycogen contents as much as fivefold higher than those in the corresponding muscles of control animals ( Figure 2 ). The largest increases in both synthase and glycogen were noted in muscles composed primarily of fast-twitch fibres, consistent with the pattern expected of the creatine kinase promoter/enhancer elements that were used to drive expression of the transgene [37] . Several lines of evidence indicate that the increase in glycogen was due to the increase in glycogen synthase, and not to increased glucose transport. The UDP-glucose concentrations were markedly lower in transgenic muscles in vivo, consistent with the increase in glycogen synthase activity [36] . The fall in UDP-glucose concentrations is also indicative of a pull instead of a push, as a push would have been expected to increase intermediates in the pathway leading to glycogen. Levels of the insulin-sensitive glucose transporter, GLUT4, in the transgenic muscles were either the same or lower than those in the corresponding muscles of control animals [36] . When assessed by measuring the initial rates of 2-deoxyglucose uptake in diaphragm, extensor digitorum longus, or soleus muscles incubated in vitro, both the basal and insulin-stimulated rates of glucose transport in transgenic muscles were almost identical with the rates observed in the muscles from non-transgenic littermates (I.
Azpiazu, P. J. Roach, A. V. Skurat and J. C. Lawrence, Jr., unpublished work). Increasing glycogen synthase activity without increasing glucose transport should not have increased glycogen accumulation if glucose transport was rate-limiting for glycogen synthesis.
Studies of muscles from transgenic mice overexpressing GLUT4 also support the view that glycogen synthesis is not regulated solely by glucose transport activity [39, 40] . Fourfold overexpression of skeletal-muscle GLUT4 was associated with a 50% increase in the maximum rate of insulin-stimulated glucose transport but no change in the rate of glycogen synthesis measured in perfused hindlimb preparations [39] .
When incubated in vitm, extensor digitorum brevis muscles from GLUT4 transgenic mice exhibited a twofold higher basal rate of glucose transport but no difference in the rate of glycogen synthesis [40] . Interestingly, female mice lacking GLUT4 as a result of targeted gene dis- In the GT/HK model, which is an intriguing extension of the push hypothesis, Shulman and co-workers [42] have proposed that the activation of glycogen synthase by insulin does not control the rate of glycogen synthesis, but rather serves to adapt the activity of the enzyme to the metabolic flux and to prevent overaccumulation of metabolites such as G6P. In this model the increase in G6P produced by increased glucose transport would activate glycogen synthase, thereby decreasing the level of intermediates in the pathway. Although increasing synthase by transgenic expression did decrease such intermediates, the finding that overexpression of glycogen synthase was sufficient to drive glycogen accumulation in vivo supports an active role for glycogen synthase in the control of glycogen accumulation.
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Concluding remarks
In summary, although it is clear that insulin activates glycogen synthase by promoting dephosphorylation of the enzyme, the two major hypotheses put forward to explain the effect of insulin are either incorrect or incomplete. Thus the mechanism of insulin action on glycogen synthase has still not been defined. More research in this area is needed in view of the importance of glycogen synthase in the control of glycogen synthesis. Results of experiments with transgenic animals clearly demonstrate that, under appropriate conditions, increasing either glucose transport or glycogen synthase leads to glycogen accumulation. However, in evaluating results from transgenic animals, it is important to remember that long-term overexpression of an enzyme may promote secondary changes in the muscle. Consequently, the effects observed may not be representative of the acute activation of glucose transport and glycogen synthase produced by insulin. Nevertheless, since insulin activates both glucose transport and glycogen synthase, it seems likely that the stimulation of , glycogen synthesis by the hormone involves both a push and a pull.
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